154 related articles for article (PubMed ID: 32005355)
1. Prophylactic dendritic cell vaccination controls pancreatic cancer growth in a mouse model.
Shangguan A; Shang N; Figini M; Pan L; Yang J; Ma Q; Hu S; Eresen A; Sun C; Wang B; Velichko Y; Yaghmai V; Zhang Z
Cytotherapy; 2020 Jan; 22(1):6-15. PubMed ID: 32005355
[TBL] [Abstract][Full Text] [Related]
2. Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model.
Bauer C; Sterzik A; Bauernfeind F; Duewell P; Conrad C; Kiefl R; Endres S; Eigler A; Schnurr M; Dauer M
Cancer Immunol Immunother; 2014 Apr; 63(4):321-33. PubMed ID: 24384835
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model.
Lau SP; van Montfoort N; Kinderman P; Lukkes M; Klaase L; van Nimwegen M; van Gulijk M; Dumas J; Mustafa DAM; Lievense SLA; Groeneveldt C; Stadhouders R; Li Y; Stubbs A; Marijt KA; Vroman H; van der Burg SH; Aerts J; van Hall T; Dammeijer F; van Eijck CHJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690771
[TBL] [Abstract][Full Text] [Related]
4. A pancreatic tumor-specific biomarker characterized in humans and mice as an immunogenic onco-glycoprotein is efficient in dendritic cell vaccination.
Collignon A; Perles-Barbacaru AT; Robert S; Silvy F; Martinez E; Crenon I; Germain S; Garcia S; Viola A; Lombardo D; Mas E; Béraud E
Oncotarget; 2015 Sep; 6(27):23462-79. PubMed ID: 26405163
[TBL] [Abstract][Full Text] [Related]
5. Magnetic resonance imaging monitoring therapeutic response to dendritic cell vaccine in murine orthotopic pancreatic cancer models.
Pan L; Shang N; Shangguan J; Figini M; Xing W; Wang B; Sun C; Yang J; Zhang Y; Hu S; Ma Q; Wang J; Velichko Y; Yaghmai V; Benson AB; Zhang Z
Am J Cancer Res; 2019; 9(3):562-573. PubMed ID: 30949410
[TBL] [Abstract][Full Text] [Related]
6. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
[TBL] [Abstract][Full Text] [Related]
7. Irreversible electroporation ablation overcomes tumor-associated immunosuppression to improve the efficacy of DC vaccination in a mice model of pancreatic cancer.
Yang J; Eresen A; Shangguan J; Ma Q; Yaghmai V; Zhang Z
Oncoimmunology; 2021 Feb; 10(1):1875638. PubMed ID: 33643692
[TBL] [Abstract][Full Text] [Related]
8. MRI radiomics for early prediction of response to vaccine therapy in a transgenic mouse model of pancreatic ductal adenocarcinoma.
Eresen A; Yang J; Shangguan J; Li Y; Hu S; Sun C; Velichko Y; Yaghmai V; Benson AB; Zhang Z
J Transl Med; 2020 Feb; 18(1):61. PubMed ID: 32039734
[TBL] [Abstract][Full Text] [Related]
9. Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice.
DeMatos P; Abdel-Wahab Z; Vervaert C; Seigler HF
Cell Immunol; 1998 Apr; 185(1):65-74. PubMed ID: 9636684
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
11. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
[TBL] [Abstract][Full Text] [Related]
12. TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer.
Perez-Penco M; Weis-Banke SE; Schina A; Siersbæk M; Hübbe ML; Jørgensen MA; Lecoq I; Lara de la Torre L; Bendtsen SK; Martinenaite E; Holmström MO; Madsen DH; Donia M; Ødum N; Grøntved L; Andersen MH
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600556
[TBL] [Abstract][Full Text] [Related]
13. Monitoring of in vivo function of superparamagnetic iron oxide labelled murine dendritic cells during anti-tumour vaccination.
Tavaré R; Sagoo P; Varama G; Tanriver Y; Warely A; Diebold SS; Southworth R; Schaeffter T; Lechler RI; Razavi R; Lombardi G; Mullen GE
PLoS One; 2011; 6(5):e19662. PubMed ID: 21637760
[TBL] [Abstract][Full Text] [Related]
14. 1-MT enhances potency of tumor cell lysate-pulsed dendritic cells against pancreatic adenocarcinoma by downregulating the percentage of Tregs.
Li Y; Xu J; Zou H; Wang C
J Huazhong Univ Sci Technolog Med Sci; 2010 Jun; 30(3):344-8. PubMed ID: 20556579
[TBL] [Abstract][Full Text] [Related]
15. Tissue localization of tumor antigen-loaded mouse dendritic cells applied as an anti-tumor vaccine and their influence on immune response.
Rossowska J; Pajtasz-Piasecka E; Szyda A; Zietara N; Duś D
Folia Histochem Cytobiol; 2007; 45(4):349-55. PubMed ID: 18165174
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model.
Bauer C; Bauernfeind F; Sterzik A; Orban M; Schnurr M; Lehr HA; Endres S; Eigler A; Dauer M
Gut; 2007 Sep; 56(9):1275-82. PubMed ID: 17395611
[TBL] [Abstract][Full Text] [Related]
17. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.
Koido S; Homma S; Okamoto M; Takakura K; Mori M; Yoshizaki S; Tsukinaga S; Odahara S; Koyama S; Imazu H; Uchiyama K; Kajihara M; Arakawa H; Misawa T; Toyama Y; Yanagisawa S; Ikegami M; Kan S; Hayashi K; Komita H; Kamata Y; Ito M; Ishidao T; Yusa S; Shimodaira S; Gong J; Sugiyama H; Ohkusa T; Tajiri H
Clin Cancer Res; 2014 Aug; 20(16):4228-39. PubMed ID: 25056373
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells.
Kim JE; Jin DH; Lee WJ; Hur D; Wu TC; Kim D
Pharmacol Res; 2013 May; 71():23-33. PubMed ID: 23428347
[TBL] [Abstract][Full Text] [Related]
19. Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma.
Leao IC; Ganesan P; Armstrong TD; Jaffee EM
Clin Transl Sci; 2008 Dec; 1(3):228-39. PubMed ID: 20357913
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cells pulsed with alpha-galactosylceramide induce anti-tumor immunity against pancreatic cancer in vivo.
Nagaraj S; Ziske C; Strehl J; Messmer D; Sauerbruch T; Schmidt-Wolf IG
Int Immunol; 2006 Aug; 18(8):1279-83. PubMed ID: 16772371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
